.jpeg)
2026-08-07 07:13:02
Belzutifan is the first approved hypoxia-inducible factor-2α (HIF-2α) inhibitor, indicated for VHL disease-associated tumors, advanced renal cell carcinoma, and pheochromocytoma/paraganglioma. This article provides a systematic overview of its approved indications, adult and pediatric weight-based dosing, administration guidelines, drug interactions, and safety monitoring requirements to support standardized clinical use.
2026-08-07 06:55:55
Encorafenib is an oral selective BRAF V600 kinase inhibitor used in combination with binimetinib or cetuximab for BRAF-mutant melanoma, metastatic colorectal cancer, and non-small cell lung cancer. This article provides a systematic review of its label highlights, tumor-specific dosing schedules, administration timing, drug interactions, and special population guidance to support standardized clinical use.
2026-08-07 06:49:51
Tazemetostat is the world's first approved oral EZH2 methyltransferase inhibitor, targeting epigenetic dysregulation in follicular lymphoma and epithelioid sarcoma. This article provides a comprehensive overview of its mechanism of action, approved indications, efficacy data, standard starting and maintenance dosing, dose modification protocols, and the critical safety alert regarding its global market withdrawal in March 2026 due to secondary hematologic malignancy risk.
2026-08-07 06:44:53
On August 5, 2026, the U.S. FDA approved Takeda's oral tablet Orzeyful (oveporexton) for adults with Narcolepsy Type 1 (NT1). As the first-in-class selective OX2 receptor agonist targeting the orexin pathway, Orzeyful moves beyond symptomatic relief to address the underlying orexin deficiency, simultaneously improving excessive daytime sleepiness, cataplexy, and disrupted nighttime sleep.
2026-08-06 07:53:13
Alpelisib (Piqray) and inavolisib (Itovebi) both target the PI3Kα pathway in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, yet their approved indications, combination partners, and evidence bases differ. This article compares the two agents across treatment line, clinical evidence, and safety considerations.
2026-08-06 07:40:26
Selumetinib (Koselugo) is the first approved MEK1/2 inhibitor for symptomatic, inoperable plexiform neurofibromas associated with Neurofibromatosis Type 1 (NF1), offering a precision-targeted therapy that reduces tumor volume and alleviates disease-related symptoms in children and adults.
2026-08-06 07:11:28
Phase 3 FIGHT-302 data presented at the 2026 ASCO Annual Meeting demonstrate that pemigatinib (Pemazyre) as first-line monotherapy significantly prolongs progression-free survival versus gemcitabine plus cisplatin in patients with FGFR2-rearranged unresectable cholangiocarcinoma, establishing a new precision-targeted standard for this molecularly defined population.
2026-08-06 06:54:38
Selpercatinib (Retevmo) is the first approved highly selective RET kinase inhibitor, dosed twice daily at 120 mg or 160 mg based on body weight, indicated for RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and other RET-altered malignancies.
2026-08-06 06:49:15
Mitotane is the cornerstone drug for adrenocortical carcinoma treatment, yet its side-effect profile extends well beyond common gastrointestinal discomfort to include adrenal insufficiency, neurological effects, and hepatic changes, necessitating systematic monitoring and proactive clinical management.
2026-08-06 06:43:18
Ponatinib is a third-generation tyrosine kinase inhibitor designed to target the BCR::ABL1 oncoprotein, offering a precision therapy option for Philadelphia chromosome-positive leukemias, particularly in patients harboring the T315I mutation or exhibiting resistance to prior TKIs.
2026-08-05 03:49:14
Axitinib is a highly selective oral VEGFR tyrosine kinase inhibitor approved for advanced renal cell carcinoma (RCC) as first-line combination therapy and second-line monotherapy. This article reviews its indications, composition, mechanism of action, critical pre-treatment warnings, and drug interactions to support safe clinical use.
2026-08-05 03:41:49
Cabergoline is a long-acting dopamine D2 receptor agonist and a first-line treatment for hyperprolactinemia. This article explains its pharmacological mechanism and highlights four critical warnings—cardiac valve disease, orthostatic hypotension, neuropsychiatric effects, and pregnancy/lactation—along with contraindications and standard dosing.
